Wockhardt Hit With Rs 5 Crore Customs Penalty, Rs 10 Crore Redemption Fine Over API Misclassification
Mumbai: Wockhardt Limited has received an adjudication order from the Commissioner of Customs, Nhava Sheva-II, imposing a penalty of Rs 5 crore and a redemption fine of Rs 10 crore in connection with the alleged mis-classification of an Active Pharmaceutical Ingredient (API) exported by the company.
The Commissioner of Customs, NS-II, Centralized Adjudication Cell at Jawaharlal Nehru Custom House, Nhava Sheva, imposed the Rs 5 crore penalty under Section 114(iii) of the Customs Act, 1962.
In addition, the company has been directed to pay a redemption fine of Rs 10 crore in lieu of confiscation of the goods allegedly mis-declared by Wockhardt under Section 125(1) of the Customs Act, 1962.
Also Read: Wockhardt Gets CDSCO Nod for Antibiotic Zaynich in Complicated UTIs
The order also levied a penalty of Rs 1 crore on Dr Aravind Y Merwade, an officer of the company, under Section 114(iii) of the Customs Act in connection with the alleged mis-classification.
Wockhardt said it is confident about the merits of its case and is taking necessary steps to challenge the order through an appeal before the appropriate authority. The company stated that, apart from the monetary fine and penalties, the order would not have a material impact on its financials, operations or other activities.
Also Read: Wockhardt to exit US generic pharmaceutical segment
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.